# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

> **NCT07142707** · PHASE1 · RECRUITING · sponsor: **MBX Biosciences** · enrollment: 124 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** MBX 4291
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07142707
- **Lead sponsor:** MBX Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-03
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07142707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07142707, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07142707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*